Merck & Co. Inc. (MRK): Price and Financial Metrics


Merck & Co. Inc. (MRK): $74.89

-4.27 (-5.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MRK POWR Grades


  • MRK scores best on the Growth dimension, with a Growth rank ahead of 96.78% of US stocks.
  • MRK's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • MRK ranks lowest in Momentum; there it ranks in the 13th percentile.

MRK Stock Summary

  • Merck & Co Inc's market capitalization of $207,834,667,054 is ahead of 98.95% of US-listed equities.
  • MRK's went public 35.93 years ago, making it older than 92.76% of listed US stocks we're tracking.
  • In terms of volatility of its share price, MRK is more volatile than only 6.21% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Merck & Co Inc, a group of peers worth examining would be ABBV, NVS, ABT, DHR, and VZ.
  • MRK's SEC filings can be seen here. And to visit Merck & Co Inc's official web site, go to www.merck.com.

MRK Valuation Summary

  • MRK's price/earnings ratio is 34.7; this is 4.93% lower than that of the median Healthcare stock.
  • Over the past 243 months, MRK's price/sales ratio has gone up 0.7.
  • Over the past 243 months, MRK's price/sales ratio has gone up 0.7.

Below are key valuation metrics over time for MRK.

Stock Date P/S P/B P/E EV/EBIT
MRK 2021-08-31 4.0 5.8 34.7 30.5
MRK 2021-08-30 4.0 5.8 34.8 30.5
MRK 2021-08-27 4.0 5.8 34.7 30.5
MRK 2021-08-26 4.0 5.8 34.8 30.6
MRK 2021-08-25 4.0 5.9 35.0 30.7
MRK 2021-08-24 4.1 5.9 35.3 31.0

MRK Growth Metrics

  • The year over year net cashflow from operations growth rate now stands at -11.51%.
  • Its 2 year price growth rate is now at 35.87%.
  • Its year over year cash and equivalents growth rate is now at -5.98%.
MRK's revenue has moved up $466,000,000 over the prior 15 months.

The table below shows MRK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 48,548 10,460 5,571
2021-03-31 48,018 11,337 7,028
2020-12-31 47,994 10,253 7,067
2020-09-30 47,348 11,041 11,518
2020-06-30 47,194 13,094 10,478
2020-03-31 48,082 12,811 10,146

MRK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRK has a Quality Grade of B, ranking ahead of 77.57% of graded US stocks.
  • MRK's asset turnover comes in at 0.535 -- ranking 75th of 682 Pharmaceutical Products stocks.
  • XTNT, ACOR, and BDSI are the stocks whose asset turnover ratios are most correlated with MRK.

The table below shows MRK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.535 0.675 0.129
2021-03-31 0.529 0.670 0.158
2020-12-31 0.538 0.677 0.171
2020-09-30 0.542 0.712 0.276
2020-06-30 0.550 0.701 0.260
2020-03-31 0.571 0.701 0.256

MRK Price Target

For more insight on analysts targets of MRK, see our MRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $93.38 Average Broker Recommendation 1.52 (Moderate Buy)

MRK Stock Price Chart Interactive Chart >

Price chart for MRK

MRK Price/Volume Stats

Current price $74.89 52-week high $91.40
Prev. close $79.16 52-week low $70.89
Day low $74.00 Volume 34,183,287
Day high $77.50 Avg. volume 12,535,506
50-day MA $80.68 Dividend yield 3.28%
200-day MA $77.44 Market Cap 189.17B

Merck & Co. Inc. (MRK) Company Bio


Merck & Co., Inc.d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.(Source:Wikipedia)


MRK Latest News Stream


Event/Time News Detail
Loading, please wait...

MRK Latest Social Stream


Loading social stream, please wait...

View Full MRK Social Stream

Latest MRK News From Around the Web

Below are the latest news stories about Merck & Co Inc that investors may wish to consider to help them evaluate MRK as an investment opportunity.

Merck & Company (MRK) Gets a Buy Rating from Mizuho Securities

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $100.00. The company's shares closed last Wednesday at $82.28. According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 15.4% and a 42.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck & Company with a $96.36 average price target, which is a 16.4% upside from current levels.

Christine Brown on TipRanks | November 26, 2021

Merck''s anti-COVID pill ''likely not'' to be cleared for pregnant women

MISE & Agrave; DAY WASHINGTON | The anti-COVID tablet developed by Merck is effective in the treatment of the virus, estimated the United States Medicines Agency (FDA) in a preliminary report published on Friday, however, recommending that it be excluded from use in pregnant women. The publication comes ahead of a meeting of an FDA […] The post Merck''s anti-COVID pill ''likely not'' to be cleared for pregnant women first appeared on The Bobr Times .

The Bobr Times | November 26, 2021

FDA Experts Will Review Mercks COVID19 Pill After Panel Says Its Effective

Federal health regulators say an experimental COVID-19 pill from Merck is effective against the virus, but they will seek input from outside experts on the risks of birth defects and other potential problems during pregnancy. The Food and Drug Administration (FDA) posted its analysis of the pill ahead of a public meeting next week where The post FDA Experts Will Review Mercks COVID19 Pill After Panel Says Its Effective appeared first on HillReporter.com .

HillReporter.com | November 26, 2021

Mercks COVID pill shows lower efficacy in updated study

Drugmaker says final analysis of trial results showed molnupiravir showed 30 percent risk reduction.

Al Jazeera | November 26, 2021

FDA calls Merck COVID-19 pill effective, but points to safety concerns

The Food and Drug Administration (FDA) says that while Merck''s experimental COVID-19 antiviral pill is effective, the agency has yet to determine whether the medication can be safely administered during pregnancy.The FDA said a review

The Hill | November 26, 2021

Read More 'MRK' Stories Here

MRK Price Returns

1-mo -14.95%
3-mo -0.96%
6-mo 0.45%
1-year -2.97%
3-year 3.42%
5-year 42.54%
YTD -6.01%
2020 -7.20%
2019 22.27%
2018 39.95%
2017 -1.49%
2016 15.05%

MRK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full MRK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.782 seconds.